Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

CHK-Cu (copper peptide) and C-60 (branched carbon chain) are discussed as potentially more effective than minoxidil for hair regrowth. Some users are skeptical about the claim that DHT isn't the root cause of hair loss, and others are trying these products to see if they work.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Caffeine's effectiveness in reversing hair loss is debated, with some users skeptical about caffeine-based products like Alpecin. Alternatives like Nizoral are suggested, but results vary, and some experience side effects from treatments that lower DHT.

The conversation is about hair loss treatments, specifically discussing GHK-Cu, with some users suggesting Minoxidil as more effective. OP is looking for a GHK-Cu product available in Europe.

A 22-year-old male shared his one-year progress using dutasteride, minoxidil, and ketoconazole shampoo for hair regrowth, showing significant improvement. Users discussed the effectiveness of these treatments, with some confusion about ketamine, and shared their own experiences and questions about dosages and side effects.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

A 25-year-old male shared his one-year hair loss progress using oral finasteride, oral minoxidil, and weekly ketoconazole, noting stabilized hair loss but no recent improvement. He is considering a hair transplant and possibly PRP sessions, while planning to continue medication.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

The user regrets not using medication after a failed hair transplant and is now using a combination of minoxidil, finasteride, derma rolling, oils, and ketoconazole shampoo to try to improve hair regrowth. They are seeking feedback on progress and considering further treatment options.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The user experienced severe side effects from finasteride and is considering a hair transplant in Australia, specifically mentioning interest in the Knudsen clinic. Concerns were raised about post-surgery hair recession and the potential need for ongoing finasteride use to maintain results.

The conversation discusses hair loss treatment using finasteride, minoxidil chews, 0.5 dermarolling, 2% ketoconazole, and a silk bonnet. The user reports positive progress and plans to continue the regimen.

The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

RU58841 is used to eliminate scalp itch. Users discuss difficulty finding reliable and affordable sources.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Switching from ketoconazole to a ciclopirox and zinc pyrithione shampoo significantly reduced hair fall. The user is considering whether to continue using ketoconazole occasionally or combine both shampoos weekly.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.